HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
RC 552
structure in first source
Also Known As:
RC-552
Networked:
2
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Carbohydrates: 22023
Glycoconjugates: 1353
Glycolipids: 2799
RC 552: 2
Lipids: 114793
Glycolipids: 2799
RC 552: 2
Experts
1.
Elliott, G T
: 1 article (07/2000)
2.
Gross, G J
: 1 article (07/2000)
3.
Moore, J
: 1 article (07/2000)
4.
Sowell, C G
: 1 article (07/2000)
5.
Walker, E B
: 1 article (07/2000)
6.
Weber, P A
: 1 article (07/2000)
Related Diseases
1.
Ischemia
07/01/2000 - "
Intravenous pretreatment with RC-552 (35 microg/kg) either 24 h or 10 min prior to five 5 min repetitive cycles of ischemia and reperfusion significantly improved regional myocardial segment shortening (percentage of control) at all time points during 2 h of reperfusion in dogs.
"
07/01/2000 - "
These effects of RC-552 in either cardiac injury model occurred independent of differences in AAR, transmural blood flow during ischemia or hemodynamics throughout the experiment.
"
12/01/1999 - "
Adult mice were pretreated with vehicle or RC-552 (350 microg/kg ip, n = 7 mice/group) 24 h before global ischemia and reperfusion in a Langendorff isolated, perfused heart model.
"
12/01/1999 - "
Acute buffer perfusion with RC-552 (0.1, 1.0, or 2.5 microg/ml) for 8 min immediately before ischemia-reperfusion did not reduce infarct size significantly.
"
07/01/2000 - "
Administration of the non-specific inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine (30 mg/kg, subcutaneously) 1 h prior to ischemia blocked the ability of RC-552 (35 microg/kg, 24 h pretreatment) to reduce infarct size.
"
2.
Myocardial Infarction
12/01/1999 - "
Myocardial infarct size was significantly reduced from 19.2 +/- 2.0% in vehicle to 8.2 +/- 2.9% in RC-552 group (P < 0.05).
"
07/01/2000 - "
Likewise, RC-552 did not induce secretion of the proinflammatory cytokines TNF, IL-6 or IL-8 from THP-1 cells or alter the expression of adhesion molecules on human neutrophils at concentrations up to 10 microg/ml. MLA was active in these systems at concentrations in the range 0.1-1.0 microg/ml. In conclusion, RC-552 reduces myocardial infarct size and stunning in dogs in the absence of residual immunomodulatory activity.
"
3.
Infarction (Infarctions)
12/01/1999 - "
In addition, RC-552 failed to reduce infarct size in isolated hearts from iNOS knockout mice (27.1 +/- 2.8%) compared with that in hearts from control knockout mice without drug treatment (22.9 +/- 5.4%).
"
07/01/2000 - "
RC-552 administered to dogs as a bolus intravenous dose (35-70 microg/kg) either 24 h or 10 min prior to 60 min of regional myocardial ischemia and 3 h of reperfusion significantly (P<0.05 v control) reduced infarct size (IS) as assessed by triphenyltetrazolium staining from 27.0+/-2.3% of the area-at-risk (AAR) to 13.3+/-2.2% and 15.0+/-3.0%, respectively.
"
07/01/2000 - "
The novel glycolipid RC-552 attenuates myocardial stunning and reduces infarct size in dogs.
"
12/01/1999 - "
Acute buffer perfusion with RC-552 (0.1, 1.0, or 2.5 microg/ml) for 8 min immediately before ischemia-reperfusion did not reduce infarct size significantly.
"
07/01/2000 - "
Administration of the non-specific inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine (30 mg/kg, subcutaneously) 1 h prior to ischemia blocked the ability of RC-552 (35 microg/kg, 24 h pretreatment) to reduce infarct size.
"
4.
Myocardial Stunning (Stunned Myocardium)
07/01/2000 - "
The novel glycolipid RC-552 attenuates myocardial stunning and reduces infarct size in dogs.
"
5.
Myocardial Ischemia (Ischemic Heart Diseases)
07/01/2000 - "
RC-552 administered to dogs as a bolus intravenous dose (35-70 microg/kg) either 24 h or 10 min prior to 60 min of regional myocardial ischemia and 3 h of reperfusion significantly (P<0.05 v control) reduced infarct size (IS) as assessed by triphenyltetrazolium staining from 27.0+/-2.3% of the area-at-risk (AAR) to 13.3+/-2.2% and 15.0+/-3.0%, respectively.
"
Related Drugs and Biologics
1.
Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
2.
Interleukin-8 (Interleukin 8)
3.
Cytokines
4.
Interleukin-6 (Interleukin 6)
5.
Pyrogens
6.
Glycolipids
7.
Buffers
8.
monophosphoryl lipid A
9.
triphenyltetrazolium
10.
pimagedine (aminoguanidine)